Bedfont Scientific Ltd receives FDA clearance for NObreath速 FeNO monitor

UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation.

Related Keywords

United States ,United Kingdom ,Americans ,American ,Pamela Jackson ,Nobreath Fe ,Chris Maclachlan ,Jano Cowan ,Taylor Francis ,D Robin Taylor ,Coumou Hbel ,Andrewd Smith ,Jason Smith ,Gabrielle Monti Sheehan ,Centre For Disease Control ,Bedfont Scientific Ltd ,Drug Administration ,Bedfont Scientific ,Fractional Exhaled Nitric Oxide ,Healthcare Professional ,Managing Director ,Disease Control ,Standardized Procedures ,Offline Measurement ,Exhaled Lower Respiratory Nitric Oxide ,Nasal Nitric Oxide ,American Journal ,Critical Care Medicine ,Sue Filsell ,Diagnosing Asthma ,Exhaled Nitric Oxide Measurements ,Nitric Oxide Predicts Asthma Exacerbation ,Airway Inflammation ,Asthma ,Wood ,Inflammation ,Nitric Oxide ,Espiratory ,